Cargando…
Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus
BACKGROUND: Diabetes mellitus (DM) increases the risk of TB disease and poor treatment outcomes such as delayed sputum culture conversion due to inadequate drug exposure. Therapeutic drug monitoring (TDM) has improved these outcomes in some settings. METHODS: To compare treatment outcomes in program...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union Against Tuberculosis and Lung Disease
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904402/ https://www.ncbi.nlm.nih.gov/pubmed/36853114 http://dx.doi.org/10.5588/ijtld.22.0448 |
_version_ | 1784883607439933440 |
---|---|
author | Alkabab, Y. Warkentin, J. Cummins, J. Katz, B. Denison, B. M. Bartok, A. Khalil, A. Young, L. R. Timme, E. Peloquin, C. A. Ashkin, D. Houpt, E. R. Heysell, S. K. |
author_facet | Alkabab, Y. Warkentin, J. Cummins, J. Katz, B. Denison, B. M. Bartok, A. Khalil, A. Young, L. R. Timme, E. Peloquin, C. A. Ashkin, D. Houpt, E. R. Heysell, S. K. |
author_sort | Alkabab, Y. |
collection | PubMed |
description | BACKGROUND: Diabetes mellitus (DM) increases the risk of TB disease and poor treatment outcomes such as delayed sputum culture conversion due to inadequate drug exposure. Therapeutic drug monitoring (TDM) has improved these outcomes in some settings. METHODS: To compare treatment outcomes in programs with routine TDM vs. programs that did not use TDM, we conducted a retrospective study among people with DM and TB at health departments in four US states. RESULTS: A total of 170 patients were enrolled (73 patients in the non-TDM group and 97 patients in the TDM group). Days to sputum culture conversion and total treatment duration were significantly shorter in the TDM group vs. the non-TDM group. In adjusted analyses, patients who underwent TDM were significantly more likely to achieve sputum culture conversion at 2 months (P = 0.007). CONCLUSION: TDM hastened microbiological cure from TB among people with DM and a high risk for poor treatment outcomes in the programmatic setting. |
format | Online Article Text |
id | pubmed-9904402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | International Union Against Tuberculosis and Lung Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-99044022023-02-09 Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus Alkabab, Y. Warkentin, J. Cummins, J. Katz, B. Denison, B. M. Bartok, A. Khalil, A. Young, L. R. Timme, E. Peloquin, C. A. Ashkin, D. Houpt, E. R. Heysell, S. K. Int J Tuberc Lung Dis Original Articles BACKGROUND: Diabetes mellitus (DM) increases the risk of TB disease and poor treatment outcomes such as delayed sputum culture conversion due to inadequate drug exposure. Therapeutic drug monitoring (TDM) has improved these outcomes in some settings. METHODS: To compare treatment outcomes in programs with routine TDM vs. programs that did not use TDM, we conducted a retrospective study among people with DM and TB at health departments in four US states. RESULTS: A total of 170 patients were enrolled (73 patients in the non-TDM group and 97 patients in the TDM group). Days to sputum culture conversion and total treatment duration were significantly shorter in the TDM group vs. the non-TDM group. In adjusted analyses, patients who underwent TDM were significantly more likely to achieve sputum culture conversion at 2 months (P = 0.007). CONCLUSION: TDM hastened microbiological cure from TB among people with DM and a high risk for poor treatment outcomes in the programmatic setting. International Union Against Tuberculosis and Lung Disease 2023-02 2023-02-01 /pmc/articles/PMC9904402/ /pubmed/36853114 http://dx.doi.org/10.5588/ijtld.22.0448 Text en © 2023 The Union https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Original Articles Alkabab, Y. Warkentin, J. Cummins, J. Katz, B. Denison, B. M. Bartok, A. Khalil, A. Young, L. R. Timme, E. Peloquin, C. A. Ashkin, D. Houpt, E. R. Heysell, S. K. Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus |
title | Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus |
title_full | Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus |
title_fullStr | Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus |
title_full_unstemmed | Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus |
title_short | Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus |
title_sort | therapeutic drug monitoring and tb treatment outcomes in patients with diabetes mellitus |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904402/ https://www.ncbi.nlm.nih.gov/pubmed/36853114 http://dx.doi.org/10.5588/ijtld.22.0448 |
work_keys_str_mv | AT alkababy therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT warkentinj therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT cumminsj therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT katzb therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT denisonbm therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT bartoka therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT khalila therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT younglr therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT timmee therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT peloquinca therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT ashkind therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT houpter therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus AT heysellsk therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus |